Alejandro González-Motta

ASTRO is proud to share the signing of a collaboration agreement with SOLAR, a federation of 13 national radiation oncology societies across Central and South America. This milestone reflects a shared commitment to collaboration & advancing radiation oncology globally. We look forward to working with our colleagues across the SOLAR network. @acro_colombia @Solar_Latam @linaloa86282374

NRG-CC014 (PREEMPT) closed after enrolling 280 patients in only 11 months, well ahead of schedule — remarkable effort made possible by the commitment & teamwork of our participating sites. thanks to our dedicated sites! @ErinGillespieMD @JonathanYangMD nrgoncology.org/Home/News/Post…

📢 New editorial online! #SABR may help delay systemic therapy in oligometastatic RCC ⏳ • Great local control 🎯 • Minimal side effects ✅ 🔗 authors.elsevier.com/c/1mxzu1Hx52Ns… 🙏 Grateful to be invited, special thanks to @_ShankarSiva

SBRT is reshaping oligometastatic prostate cancer 🎯 It can delay systemic therapy & prolong disease control⏳ Congrats to all co-authors especially Macarena Teja & Miguel Ángel Berenguer💪 Honored to publish with @VedangMurthy & @GiuliaMarvaso84 ⭐ 🔗 mdpi.com/2075-1729/16/4…

Editorial CATNON IDHmt Grade 3 Astrocytoma · NO benefit concurrent temozolomide · Sig benefit w/adjuvant TMZ · MGMT NOT prognostic · Poor prog CDKN2A/B homo deletion, PDGFRA amp, methy profile academic.oup.com/neuro-oncology…

Fantastic news for renal cancer patients. Latest NICE guideline recommends #SABR to primary RCC for selected patients with stage IA and IB disease! nice.org.uk/guidance/ng256… #radonc #medonc #SBRT Big thanks to @_ShankarSiva who has pioneered this important treatment option

🔴Online now: UK NICE 2026 guideline for the diagnosis and management of kidney cancer, @NICEComms Read here: thelancet.com/journals/lanon…

ReRT with Spine SBRT 107 lesions most 18-24Gy/1 or 30-36Gy/3 Median time to reRT 12 mo 1 Yr LC 88% No RM, 5 cases periph neuropathy sciencedirect.com/science/articl…

✈️ Esta semana estaré en Colombia 🇨🇴 como ponente en el congreso de ASOPROCÁNCER. 🙏 Gracias por la invitación, especialmente a Lina Loaiza, presidenta de la Sociedad Colombiana de Radioterapia Oncológica. 🔗 asoprocancer.co/programa #RadiationOncology #OncologíaRadioterapica

Someone suggested I make a table summarizing the video. Here it is!

#EAU26 Dr. Fonteyne on MDT in oligometastatic prostate cancer: Evidence is growing, but context matters. 🔹 STOMP & ORIOLE: MDT → excellent local control, delays progression 🔹 RADIOSA: MDT + ADT > MDT alone for PFS 🔹 ARTO: MDT + SOC improved PFS and may signal OS benefit Yet major gaps remain: • Most data come from metachronous disease • Evidence in de novo oligometastatic HSPC is limited • Patient selection is key @uroweb @UroToday

Radiotherapy to primary tumor, What for? Presentation by @AlbertoBossial @GustaveRoussy. #EAU26 written coverage by @chavarriagaj @PSH_Urology > bit.ly/4bbehVx @Uroweb

What evidence do we have from intensification with SBRT? Presentation by Valerie Fonteyne, MD, PhD @uzgent. #EAU26 written coverage by @chavarriagaj @PSH_Urology > bit.ly/4rIbbxm @Uroweb

#EAU26 Dr. Bossi asks a key question: RT to the primary tumor in de novo mHSPC… what for? 🎯 Possible goals: • Improve OS → signal mainly in low-volume disease (STAMPEDE) • Improve rPFS → consistent signal across pooled analyses • Delay local GU complications • Delay progression to mCRPC 💬 Key point: these goals should be discussed with patients, considering their preferences and expectations. @uroweb @UroToday

#EAU26 @ChrisSweens1: the field is reaching a consensus in mHSPC. ADT + ARPI for nearly all patients, then personalize intensification: • SBRT for low-volume • Prostate RT in synchronous disease • Docetaxel if high-volume and chemofit 🕒 The hope for the future: biomarkers to guide therapy, global access, and drug prices coming down so evidence-based care becomes feasible worldwide. @uroweb @UroToday

#EAU26 Congrats to the FASTRACK teams @_ShankarSiva. SBRT for RCC now has greater prospective data than all other ablative treatments and is a guideline supported SOC. Excited to continue to expand its use through the conduct of well designed clinical trials. Patients want a non-invasive option, but we must continue to generate these excellent results. @ASTRO_org @NCCN @NRGonc @ASCO

#ATENCIÓN Kevin merece ser despedido con la dignidad y el amor que siempre lo rodearon, y su mamá merece sentir que no está sola. Unámonos para acompañar a Katerine Pico, sostenerla y demostrarle que su hijo dejó una huella imborrable en todos nosotros. Hoy más que nunca, #TodosSomosKevin 💜 Si deseas apoyar a su familia en este momento tan difícil, puedes hacerlo aquí: vaki.co/vaki/TodosSomo…

#GU26 @TheLancet Extremely proud to co-lead with @AmarUKishan and all investigators in MARCAP for helping make these exciting results possible. Presents POSEIDON assessing use of hormone therapy use and duration with post-op RT for recurrent PCa: An individual patient data meta-analysis of 6 trials thelancet.com/journals/lance… @ASCO

Research summary here: jamanetwork.com/journals/jama/…

Phase 3 randomized trial of SRS v HA-WBRT meets its primary endpoint. jamanetwork.com/journals/jama/…